PharmaEngine, Inc.: peers
PharmaEngine, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Jyong Biotech Ltd.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | PharmaEngine, Inc.base 4162.TWO · 🇹🇼 TW Percentile in Healthcare Percentile in Taiwan | Jyong Biotech Ltd. MENS · 🇹🇼 TW Percentile in Healthcare Percentile in Taiwan | Microbio Co., Ltd. 4128.TWO · 🇹🇼 TW Percentile in Consumer Defensive Percentile in Taiwan | Adimmune Corporation 4142.TW · 🇹🇼 TW Percentile in Healthcare Percentile in Taiwan | TCM Biotech International Corp. 4169.TWO · 🇹🇼 TW Percentile in Healthcare Percentile in Taiwan | Tanvex BioPharma, Inc. 6541.TW · 🇹🇼 TW Percentile in Healthcare Percentile in Taiwan | OBI Pharma, Inc. 4174.TWO · 🇹🇼 TW Percentile in Healthcare Percentile in Taiwan | Sinphar Pharmaceutical Co., Ltd. 1734.TW · 🇹🇼 TW Percentile in Healthcare Percentile in Taiwan | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $220 MNov 19, 2026 · Market data2nd of 8 | $154 MAug 1, 2026 · Market data8th of 8 | $212 MNov 19, 2026 · Market data3rd of 8 | $207 MNov 19, 2026 · Market data4th of 8 | $206 MNov 19, 2026 · Market data5th of 8 | $197 MNov 19, 2026 · Market data6th of 8 | $279 MNov 19, 2026 · Market data1st of 8 | $175 MNov 19, 2026 · Market data7th of 8 | $207 M8 ranked |
| Net income (Higher is better) | —— | $-5 MFY2025 · SEConly one with it | —— | —— | —— | —— | —— | —— | $-5 M— |
| Employees (Better neither way: ranked highest first) | —— | 27December 31, 2025 · Profileonly one with it | —— | —— | —— | —— | —— | —— | 27— |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | ———— | 207.1×price Nov 19, 2026 · Market dataonly one with it96th97th | ———— | ———— | ———— | ———— | 207.1×— |
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | 3.8×price Nov 19, 2026 · Market dataonly one with it51st68th | ———— | ———— | ———— | ———— | 3.8×— |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | 1.0×price Nov 19, 2026 · Market dataonly one with it19th21st | ———— | ———— | ———— | ———— | 1.0×— |
| Financial strength | |||||||||
| Interest cover (Higher is better) | ———— | -1.0×FY2025 · SEConly one with it66th— | ———— | ———— | ———— | ———— | ———— | ———— | -1.0×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 0 of 6FY2025 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 0% passed— |
| Growth checks (Higher is better) | —— | 0 of 1FY2025 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 0% passed— |
| Profitability checks (Higher is better) | —— | 0 of 1FY2025 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 0% passed— |
| Financial health checks (Higher is better) | —— | 0 of 3FY2025 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 0% passed— |
| Shareholder returns checks (Higher is better) | —— | 0 of 1FY2025 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 0% passed— |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 0.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | —— | —— | —— | —— | —— | —— | 0.6%— |
| Institutions holding (Better neither way: ranked highest first) | —— | 172026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | —— | —— | —— | —— | —— | —— | 17— |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | +0.0 pp2026-Q2 against 2026-Q1 · 13Fonly one with it | —— | —— | —— | —— | —— | —— | +0.0 pp— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = PharmaEngine, Inc.: Taiwan Stock Exchange and Taipei Exchange, issued shares times the close; Jyong Biotech Ltd.: How market caps are worked out; Microbio Co., Ltd.: Taiwan Stock Exchange and Taipei Exchange, issued shares times the close; Adimmune Corporation: Taiwan Stock Exchange and Taipei Exchange, issued shares times the close; TCM Biotech International Corp.: Taiwan Stock Exchange and Taipei Exchange, issued shares times the close; Tanvex BioPharma, Inc.: Taiwan Stock Exchange and Taipei Exchange, issued shares times the close; OBI Pharma, Inc.: Taiwan Stock Exchange and Taipei Exchange, issued shares times the close; Sinphar Pharmaceutical Co., Ltd.: Taiwan Stock Exchange and Taipei Exchange, issued shares times the close.
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | P/E ratio | In its sector | In its country |
|---|---|---|---|
| PharmaEngine, Inc. | — | — | — |
| Jyong Biotech Ltd. | — | — | — |
| Microbio Co., Ltd. | — | — | — |
| Adimmune Corporation | 207.1× | 96th percentile in Healthcaremedian 30.0×, 254 companies | 97th percentile in Taiwanmedian 16.7×, 221 companies |
| TCM Biotech International Corp. | — | — | — |
| Tanvex BioPharma, Inc. | — | — | — |
| OBI Pharma, Inc. | — | — | — |
| Sinphar Pharmaceutical Co., Ltd. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Fewer than two years of revenue are on file for these companies.
Rank in the group
Ranks need two fiscal years with the figure for at least two of these companies.
Suggested peers of PharmaEngine, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Jyong Biotech Ltd.MENS · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $154 M market cap against $220 M · Same country: Taiwan · Ratios of the last two fiscal years on fileMarket cap $154 M (Aug 1, 2026)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Microbio Co., Ltd.4128.TWO · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $212 M market cap against $220 M · Same country: TaiwanMarket cap $212 M (Nov 19, 2026)95 of 100 (industry or sector 50 + size 30 + country 15)In the group
- Adimmune Corporation4142.TW · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $207 M market cap against $220 M · Same country: TaiwanMarket cap $207 M (Nov 19, 2026) · revenue $54 M (year to December 2021)95 of 100 (industry or sector 50 + size 30 + country 15)In the group
- TCM Biotech International Corp.4169.TWO · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $206 M market cap against $220 M · Same country: TaiwanMarket cap $206 M (Nov 19, 2026)95 of 100 (industry or sector 50 + size 30 + country 15)In the group
- Tanvex BioPharma, Inc.6541.TW · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $197 M market cap against $220 M · Same country: TaiwanMarket cap $197 M (Nov 19, 2026)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- OBI Pharma, Inc.4174.TWO · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $279 M market cap against $220 M · Same country: TaiwanMarket cap $279 M (Nov 19, 2026)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- Sinphar Pharmaceutical Co., Ltd.1734.TW · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $175 M market cap against $220 M · Same country: TaiwanMarket cap $175 M (Nov 19, 2026)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- TaiGen Biopharmaceuticals Holdings Limited4157.TWO · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $171 M market cap against $220 M · Same country: TaiwanMarket cap $171 M (Nov 19, 2026)93 of 100 (industry or sector 50 + size 28 + country 15)+ Add
- Savior Lifetec Corporation4167.TWO · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $170 M market cap against $220 M · Same country: TaiwanMarket cap $170 M (Nov 19, 2026)93 of 100 (industry or sector 50 + size 28 + country 15)+ Add
- Polaris Group6550.TW · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $168 M market cap against $220 M · Same country: TaiwanMarket cap $168 M (Nov 19, 2026)93 of 100 (industry or sector 50 + size 28 + country 15)+ Add
- Sinew Pharma Inc.6634.TWO · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $151 M market cap against $220 M · Same country: TaiwanMarket cap $151 M (last known, Jan 5, 2024)92 of 100 (industry or sector 50 + size 28 + country 15)+ Add
- UnicoCell Biomed Co., Ltd.6794.TWO · 🇹🇼 TaiwanSame industry: Biotechnology · Similar size: $129 M market cap against $220 M · Same country: TaiwanMarket cap $129 M (Nov 19, 2026)92 of 100 (industry or sector 50 + size 27 + country 15)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.